SCYX Q3 2022 Earnings — SCYNEXIS, Inc. Revenue & Financial Results | Market Cap Arena

SCYXSCYNEXIS, Inc.

$37M

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$2M+201.7% YoY

Gross Profit

$1M87.9% margin

Operating Income

-$22M-1400.2% margin

Net Income

-$30M-1900.1% margin

EPS (Diluted)

$-0.78

QoQ Revenue Growth

+17.7%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$112M

Total Liabilities

$95M

Stockholders' Equity

$17M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$516,000	+201.7%
Gross Profit	$1M	$371,000	+268.7%
Operating Income	-$22M	-$19M	-12.1%
Net Income	-$30M	-$605,000	-4789.9%

Revenue Segments

Product

$2M100%